Browsing by Author Sievert, W

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 16 of 16
TitleAuthor(s)Issue DateViews
 
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2019
1
 
Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage
Journal:Hepatology
Wu, ICLai, CLBui Han, SHHan, KHGordon, SCChao, YCTan, CKSievert, WTanwandee, TXu, DNeo, BLChang, TT
2010
 
Efficacy of entecavir in nucleoside-naefve patients with mildly elevated ALT
Journal:Gastroenterology
Gordon, SCHan, SHChang, TTLai, CLHan, KHChao, YCTan, CKSievert, WTanwandee, TNeo, BL
2008
127
 
Final results of a phase 1b 28-day study of ABI-H0731, a novel core inhibitor, in non-cirrhotic viremic subjects with chronic hepatitis B
Journal:Hepatology
Yuen, RMFAgarwal, KGane, EJSchwabe, .CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RConnelly, ECai, DWHuang, QColonno, RLopatin, UA
2018
50
 
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV
Proceeding/Conference:Hepatology
Gane, EJLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JLi, ZCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2018
83
 
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KGane, ESchwabe, CCheng, WSievert, WKim, DJAhn, SHLim, YSVisvanathan, KRuby, ELiaw, SColonno, RLopatin, U
2018
110
 
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 results
Proceeding/Conference:Hepatology
Bzowej, NChan, HLYLai, CLCho, MMoon, YMChao, YCHeathcote, EJMyers, RMinuk, GMarcellin, PJeffers, LSievert, WKaiser, RHarb, GChao, GCBrown, NA
2006
126
 
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis
Proceeding/Conference:Gastroenterology
Heathcote, EJChan, HLCho, MLai, CLMoon, YMChao, YCMyers, RMinuk, GMarcellin, PJeffers, LSievert, WKaiser, RChao, GBrown, N
2006
139
 
A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis
Proceeding/Conference:Journal of Hepatology
Chan, HLYLai, CLCho, MHeathcote, JMoon, Y-MChao, Y-CMyers, RMinuk, GMarcellin, PJeffers, LSievert, WKaiser, RChao, GBrown, N
2006
139
 
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, MFAgarwal, KGane, EJSchwabe, CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RHuang, QColonno, RLopatin, U
2020
31
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, ODe Ridder, FCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2021
1
 
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International
Gane, ELocarnini, SLim, THStrasser, SISievert, WCheng, WThompson, AJGiven, BDSchluep, THamilton, JBiermer, MKalmeijer, RBeumont, MLenz, ORidder, FDCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RYuen, RMF
2022
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
73
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
3
 
Three years of entecavir (etv) re-treatment of HBeAg(-) etv patients who previously discontinued ETV treatment: results from study ETV-901
Proceeding/Conference:Hepatology
Shouval, DLai, CLChang, TTGadano, AWu, SSHalota, WSievert, WTsai, NCSCZhang, HIloeje, U
2008
172
 
Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial
Journal:Annals of Internal Medicine
Chan, HLYHeathcote, EJMarcellin, PLai, CLCho, MMoon, YMChao, YCMyers, RPMinuk, GYJeffers, LSievert, WBzowej, NHarb, GKaiser, RQiao, XJBrown, NACrawford, DLim, SGChutaputti, APoynard, T
2007
112
Showing results 1 to 16 of 16